Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
2019
Abstract Background Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multi...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
39
References
575
Citations
NaN
KQI